Spinal Meningioma disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: SPN021 MIFTS: 43	Spinal Meningioma Categories: Cancer diseases, Neuronal diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Spinal Meningioma

MalaCards integrated aliases for Spinal Meningioma:

Name: Spinal Meningioma ¹¹ ¹⁹ ¹⁴ ⁷¹

Meningioma, Benign, No Icd-O Subtype ⁷¹

Spinal Cord Meningioma ¹¹

Meningioma, Spine ¹⁹

Meningioma ⁷¹

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Neuronal diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:1138

MeSH ⁴³ D008579

NCIt ⁴⁹ C6935

SNOMED-CT ⁶⁸ 189167009

UMLS ⁷¹ C0025286 C0347515 C1762616

Sources

Summaries for Spinal Meningioma

GARD: ¹⁹ Spinal meningioma is a rare type of spinal cord cancer. The spinal cord is part of the central nervous system. This tumor often affects middle-aged women. Tumors of the spinal cord can be either primary or arise from other primary tumors (metastatic), and are typically slow growing. Other features are motor deficits, sensory deficits, pain, and sphincter dysfunction. The thoracic spine (middle back) is the most common site, followed by the cervical spine (neck). These tumors are rarely seen in the lumbar region (lower back). The only proven risk factor in the development of meningioma is exposure to ionizing radiation. Also, patients with neurofibromatosis type 2 are at increased risk of developing meningioma.

MalaCards based summary: Spinal Meningioma, also known as meningioma, benign, no icd-o subtype, is related to psammomatous meningioma and neurilemmoma. An important gene associated with Spinal Meningioma is SMARCE1 (SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1), and among its related pathways/superpathways are Assembly of the pre-replicative complex and Chromatin organization. The drugs Thrombin and Tranexamic acid have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, brain and pituitary, and related phenotypes are Increased proliferation and normal

Sources

Related Diseases for Spinal Meningioma

Diseases related to Spinal Meningioma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 168)

#	Related Disease	Score	Top Affiliating Genes
1	psammomatous meningioma	30.7	TRAF7 PGR NF2
2	neurilemmoma	30.4	SMARCB1 NF2 NF1 LZTR1
3	neurofibromatosis	30.3	SMARCB1 NF2 NF1 LZTR1
4	acoustic neuroma	30.2	SMARCB1 NF2 NF1 LZTR1
5	intraventricular meningioma	30.0	TRAF7 SMARCE1 NF2
6	meningioma, familial	29.9	TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
7	neurofibromatosis, type ii	29.8	TRAF7 SMARCB1 NF2 NF1 LZTR1 EPB41
8	meningothelial meningioma	29.7	TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
9	benign meningioma	29.6	TRAF7 PGR NF2 KLF4
10	spinal cancer	29.6	TRAF7 SMARCE1 SMARCB1 NF2 NF1 LZTR1
11	microcystic meningioma	29.6	TRAF7 SMARCE1 NF2 MIB1
12	fibrous meningioma	29.0	TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
13	intracranial meningioma	28.9	TRAF7 SMARCE1 SMARCB1 PGR NF2 NF1
14	transitional meningioma	28.8	TRAF7 SMARCE1 SMARCB1 PGR NF2 KLF4
15	spinal canal and spinal cord meningioma	28.3	TRAF7 SMARCE1 SMARCC2 SMARCB1 PHF10 PGR
16	thoracic spinal canal and spinal cord meningioma	11.3
17	lumbar spinal canal and spinal cord meningioma	11.3
18	multiple spinal canal and spinal cord meningioma	11.3
19	cervical spinal canal and spinal cord meningioma	11.3
20	sacral spinal canal and spinal cord meningioma	11.3
21	cerebellopontine angle meningioma	10.3	SMARCE1 NF2
22	posterior pituitary gland neoplasm	10.3	SMARCB1 NF2
23	pineal region meningioma	10.3	SMARCB1 NF2
24	foramen magnum meningioma	10.3	TRAF7 NF2
25	schwannomatosis 1	10.3	SMARCB1 NF2
26	lung meningioma	10.3	PGR NF2
27	cerebellopontine angle tumor	10.3	SMARCB1 NF2
28	intraneural perineurioma	10.3	TRAF7 NF2
29	petroclival meningioma	10.3	TRAF7 NF2
30	spinal cord disease	10.3
31	paraplegia	10.3
32	melanotic neurilemmoma	10.3	SMARCB1 NF2
33	spinal cord ependymoma	10.2	SMARCB1 NF2
34	epithelioid neurofibroma	10.2	NF2 NF1
35	sphenoorbital meningioma	10.2	TRAF7 SMARCE1 NF2
36	optic nerve astrocytoma	10.2	SMARCB1 NF1
37	cavernous sinus meningioma	10.2	TRAF7 SMARCE1 NF2
38	kidney rhabdoid cancer	10.2	SMARCC2 SMARCB1
39	neurilemmoma of the fifth cranial nerve	10.2	NF2 NF1
40	small intestine leiomyoma	10.2	NF2 NF1
41	trigeminal nerve neoplasm	10.2	NF2 NF1
42	full schwannomatosis	10.2	SMARCB1 NF2 LZTR1
43	anaplastic ependymoma	10.2	SMARCB1 NF2
44	solitary fibrous tumor/hemangiopericytoma	10.2	TRAF7 SMARCE1 SMARCB1
45	spinal cord astrocytoma	10.2	NF2 NF1
46	epidural spinal canal neoplasm	10.2	NF2 NF1
47	petrous apex meningioma	10.2	NF2 EPB41
48	orbital cancer	10.2	NF2 NF1
49	epithelioid malignant peripheral nerve sheath tumor	10.2	SMARCB1 NF1
50	rete ovarii adenoma	10.2	NF2 NF1

Graphical network of the top 20 diseases related to Spinal Meningioma:

Sources

Symptoms & Phenotypes for Spinal Meningioma

GenomeRNAi Phenotypes related to Spinal Meningioma according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.09	ARID1A BCL7B EPB41 FAT2 KLF4 LZTR1
2	no effect	GR00402-S-2	10.09	ARID1A BCL7B EPB41 KLF4 MIB1 NF1
3	Increased proliferation	GR00094-A	8.96	NF2 SMARCB1

MGI Mouse Phenotypes related to Spinal Meningioma:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	9.97	ARID1A BCL7B FAT2 KLF4 MIB1 NF1
2	embryo	MP:0005380	9.86	ARID1A MIB1 NF1 NF2 PBRM1 PGR
3	neoplasm	MP:0002006	9.85	ARID1A KLF4 NF1 NF2 PGR SMARCB1
4	craniofacial	MP:0005382	9.63	ARID1A KLF4 LZTR1 MIB1 NF1 NF2
5	cardiovascular system	MP:0005385	9.61	ARID1A KLF4 LZTR1 MIB1 NF1 PBRM1
6	mortality/aging	MP:0010768	9.47	ARID1A BCL7B EPB41 KLF4 LZTR1 MIB1

Sources

Drugs & Therapeutics for Spinal Meningioma

Drugs for Spinal Meningioma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 168)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Thrombin

Approved, Investigational

Phase 4

Tranexamic acid

Approved

Phase 4

1197-18-8

5526

Racepinephrine

Approved, Vet_approved

Phase 4

51-43-4, 329-65-7

838 5816

Bupivacaine

Approved, Investigational

Phase 4

2180-92-9, 38396-39-3

2474

Prilocaine

Approved

Phase 4

721-50-6

4906

Fibrin Tissue Adhesive

Phase 4

Antifibrinolytic Agents

Phase 4

Hemostatics

Phase 4

Coagulants

Phase 4

Anesthetics, Local

Phase 4

Anesthetics

Phase 4

Vasoconstrictor Agents

Phase 4

Epinephryl borate

Phase 4

Bronchodilator Agents

Phase 4

Neurotransmitter Agents

Phase 4

Adrenergic beta-Agonists

Phase 4

Adrenergic alpha-Agonists

Phase 4

Adrenergic Agonists

Phase 4

Adrenergic Agents

Phase 4

Anti-Asthmatic Agents

Phase 4

Respiratory System Agents

Phase 4

Mydriatics

Phase 4

Sympathomimetics

Phase 4

Progesterone

Approved, Vet_approved

Phase 3

57-83-0

5994

Mifepristone

Approved, Investigational

Phase 3

84371-65-3

55245

Cisatracurium

Approved, Investigational

Phase 3

96946-41-7

62887

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 3

7487-88-9

Sevoflurane

Approved, Vet_approved

Phase 3

28523-86-6

5206

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 3

437-38-7

3345

Propofol

Approved, Investigational, Vet_approved

Phase 3

2078-54-8

4943

Aminolevulinic acid

Approved

Phase 3

106-60-5

137

Hormones

Phase 3

Hormone Antagonists

Phase 3

glucocorticoids

Phase 3

Contraceptives, Postcoital

Phase 3

Contraceptives, Oral

Phase 3

Contraceptive Agents

Phase 3

Progestins

Phase 3

Antihypertensive Agents

Phase 3

Photosensitizing Agents

Phase 3

Dermatologic Agents

Phase 3

Erlotinib

Approved, Investigational

Phase 1, Phase 2

183319-69-9, 183321-74-6

176870

Aldesleukin

Approved

Phase 2

110942-02-4

Sunitinib

Approved, Investigational

Phase 2

557795-19-4

5329102

Gefitinib

Approved, Investigational

Phase 2

184475-35-2

123631

Hydroxyurea

Approved

Phase 2

127-07-1

3657

Copper

Approved, Investigational

Phase 1, Phase 2

7440-50-8

27099

Trabectedin

Approved, Investigational

Phase 2

114899-77-3

108150

Verapamil

Approved

Phase 2

152-11-4, 52-53-9

2520

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Interventional clinical trials:

(show top 50) (show all 158)

#	Name	Status	NCT ID	Phase	Drugs
1	Neurocognitive Outcome Assessment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial.	Unknown status	NCT03190122	Phase 4
2	Dissection of the Outer Layer of the Lateral Wall of the Cavernous Sinus Decreases Bleeding as Compared to Direct Tumor Attack in Middle Fossa Meningiomas: A Randomized Controlled Trial	Unknown status	NCT02863484	Phase 4
3	A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery	Completed	NCT02034799	Phase 4
4	Effect of Tranexamic Acid Infusion to Reduce Intraoperative Blood Loss in Large Meningioma: A Prospective Randomized Double-blind Control Study	Not yet recruiting	NCT04386642	Phase 4	Tranexamic acid;Placebo
5	Comparison of Different Approaches for Supraclavicular Block and Their Effects on Diaphragm Muscle Function Evaluated With Diaphragm Thickening Fraction	Not yet recruiting	NCT04756050	Phase 4	Bupivacaine HCl 0.5% Injectable Solution;Prilocaine HCl % 2 injectable solution;adrenaline amp 0.5mg
6	Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial	Unknown status	NCT00517959	Phase 3
7	PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS	Unknown status	NCT01655927	Phase 3	Tranexamic Acid;Placebo: Saline
8	Double Blind Randomized Trial of the Anti-Progestational Agent Mifepristone In The Treatment of Unresectable Meningioma	Completed	NCT03015701	Phase 3	Mifepristone
9	The Effect of Magnesium Sulphate on Intraoperative Blood Loss in Meningioma Patient Undergoing Craniotomy With Tumor Removal	Completed	NCT03558516	Phase 3	Magnesium group;Normal saline group
10	Prospective Study Of Patients With Recurrent Or Incomplete Excised Benign Intercranial Meningiomas For The Evaluation Of Treatment Result With Combined Proton And Photon Irradiation To Doses 55.8 Or 63.0 CGE	Completed	NCT02947984	Phase 3
11	Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma	Recruiting	NCT03180268	Phase 3
12	A Phase 3 Multicenter Study of Gleolan (Aminolevulinic Acid Hydrochloride) to Enhance Visualization of Tumor in Patients With Newly Diagnosed or Recurrent Meningiomas	Recruiting	NCT04305470	Phase 3	Gleolan (Aminolevulinic Acid Hydrochloride/ALA/ALA-HCI)
13	A Parallel-group, Two-staged, Phase 2/3, Randomized, Multicenter Study to Evaluate the Efficacy and Safety of REC-2282 in Participants With Progressive NF2 Mutated Meningiomas	Recruiting	NCT05130866	Phase 2, Phase 3	REC-2282;Placebo
14	Observation Versus Conventional-Fractionated Radiotherapy or Radiosurgery After Non-radical Surgery for Benign Intracranial Meningiomas: A Phase III Study	Terminated	NCT00104936	Phase 3
15	A Phase II, Open-label, Single Arm Trial of Pembrolizumab for Refractory Atypical and Anaplastic Meningioma	Unknown status	NCT03016091	Phase 2	Pembrolizumab
16	IMATINIB Plus Hydroxyurea in the Treatment of Recurrent or Progressive Meningiomas: a Randomized Phase II Study	Unknown status	NCT00904735	Phase 2	hydroxyurea;imatinib mesylate
17	Combination of Everolimus and Octreotide LAR in Aggressive Recurrent Meningiomas.	Unknown status	NCT02333565	Phase 2	Everolimus;Octreotide
18	A Randomized Phase II Trial of Bevacizumab to Control Brain Radiation Damage	Completed	NCT00492089	Phase 2	bevacizumab;placebo
19	Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas	Completed	NCT01125046	Phase 2
20	Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma	Completed	NCT00045734	Phase 2	imatinib mesylate
21	A Phase I/II Trial of OSI-774 in Patients With Recurrent Malignant Gliomas and Malignant Gliomas Post Radiation Therapy	Completed	NCT00045110	Phase 1, Phase 2	erlotinib hydrochloride
22	Phase II Trial of Irinotecan in Children With Refractory Solid Tumors	Completed	NCT00004078	Phase 2	irinotecan hydrochloride
23	Phase II Study of Monthly SOM230C for Recurrent or Progressive Meningioma	Completed	NCT00859040	Phase 2	SOM230C
24	Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma	Completed	NCT00589784	Phase 2	Sunitinib
25	ZD1839 FOR Treatment Of Recurrent Or Progressive Malignant Astrocytoma Or Glioblastoma And Recurrent Or Progressive Meningioma: A Phase II Study With A Phase I Component For Patients Receiving EIAEDs	Completed	NCT00025675	Phase 2	gefitinib
26	Phase II Study of Hydroxyurea for the Treatment of Recurrent and/or Nonoperable Meningioma	Completed	NCT00006119	Phase 2	hydroxyurea
27	Phase II Study of Hydroxyurea for Unresectable Meningioma	Completed	NCT00003590	Phase 2	hydroxyurea
28	A Phase II Study of Imatinib Mesylate Plus Hydroxyurea in the Treatment of Patients With Recurrent/Progressive Meningioma	Completed	NCT00354913	Phase 2	hydroxyurea;imatinib mesylate
29	Peptide Receptor Radionuclide Therapy Administered to Participants With Meningioma With 67Cu-SARTATE™: A Single-centre, Open-label, Non- Randomised, Phase I-IIa Theranostic Clinical Trial	Completed	NCT03936426	Phase 1, Phase 2	Cu-64 SARTATE and Cu-67 SARTATE
30	Trabectedin for Recurrent Grade II or III Meningioma: a Randomized Phase II Study of the EORTC Brain Tumor Group	Completed	NCT02234050	Phase 2	Trabectedin
31	Combination of Hydroxyurea and Verapamil for Refractory Meningiomas	Completed	NCT00706810	Phase 2	Hydroxyurea;Verapamil
32	Phase II Study of Metastatic Cancer That Expresses NY-ESO-1 Using Lymphodepleting Conditioning Followed by Infusion of Anti-NY ESO-1 Murine TCR-Gene Engineered Lymphocytes	Completed	NCT01967823	Phase 2	Cyclophosphamide;Fludarabine;Aldesleukin
33	Proton Radiation for Low Grade Gliomas	Completed	NCT01024907	Phase 1, Phase 2
34	A Single Arm Phase 2 Study of the Dual mTORC1/mTORC2 Inhibitor AZD2014 Provided on an Intermittent Schedule for Neurofibromatosis 2 Patients With Progressive or Symptomatic Meningiomas	Completed	NCT02831257	Phase 2	AZD2014
35	Phase II Study to Evaluate the Efficacy of Recombinant Interferon-Alpha in the Treatment of Recurrent Unresectable Meningiomas and Malignant Meningiomas	Completed	NCT00002965	Phase 2
36	Phase I/II Trial of STI571 (NSC 716051) in Patients With Recurrent Malignant Gliomas	Completed	NCT00010049	Phase 1, Phase 2	imatinib mesylate
37	A Phase II Trial of PTK-787 in Recurrent or Progressive Meningiomas	Completed	NCT00348790	Phase 2	vatalanib
38	A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma	Recruiting	NCT02847559	Phase 2
39	A Prospective, Phase II Study of Lutetium Lu 177 Dotatate (LUTATHERA®) in Patients With Inoperable, Progressive Meningioma After External Beam Radiation Therapy	Recruiting	NCT04082520	Phase 2	Lutetium Lu 177 Dotatate
40	A Phase II Study of Stereotactic Radiosurgery in Conjunction With the PD-1 Inhibitor, Pembrolizumab for the Treatment of Recurrent Meningioma	Recruiting	NCT04659811	Phase 2	Pembrolizumab
41	A Phase I/II Study of Nivolumab Plus or Minus Ipilimumab in Combination With Multi-Fraction Stereotactic Radiosurgery for Recurrent High-Grade Radiation-Relapsed Meningioma	Recruiting	NCT03604978	Phase 1, Phase 2
42	Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations	Recruiting	NCT02523014	Phase 2	Vismodegib;FAK Inhibitor GSK2256098;Capivasertib;Abemaciclib
43	SSTR2-Targeted PET Imaging of Meningioma: Direct Comparison of Ga-68-DOTATATE and Ga-68-DOTATOC	Recruiting	NCT04298541	Phase 2	Ga-68- DOTATATE;Ga-68-DOTATOC
44	An Open-Label Phase II Study of Nivolumab in Adult Participants With Recurrent High-Grade Meningioma	Recruiting	NCT02648997	Phase 2	Nivolumab - 240 mg;Ipilimumab - 1 mg/kg;Nivolumab - 480 mg;Nivolumab - 3 mg/kg
45	A Single Arm, Open-label, Multicenter Phase II Study of 177Lu-DOTATATE Radionuclide in Adults With Progressive or High-risk Meningioma	Recruiting	NCT03971461	Phase 2	Lutathera
46	An Open-Label, Phase 2 Study of NEO100 in Participants With Residual, Progressive or Recurrent High-Grade Meningioma	Recruiting	NCT05023018	Phase 2	NEO100
47	A Phase II Study of Cabozantinib for Patients With Recurrent or Progressive Meningioma	Recruiting	NCT05425004	Phase 2	Cabozantinib
48	Innovative Trial for Understanding the Impact of Targeted Therapies in NF2 (INTUITT-NF2)	Recruiting	NCT04374305	Phase 2	Brigatinib;Neratinib
49	Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors	Recruiting	NCT03095248	Phase 2	Selumetinib
50	Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Recurrent Select Rare CNS Cancers	Recruiting	NCT03173950	Phase 2	Nivolumab

Search NIH Clinical Center for Spinal Meningioma

Sources

Genetic Tests for Spinal Meningioma

Sources

Anatomical Context for Spinal Meningioma

Organs/tissues related to Spinal Meningioma:

MalaCards : Spinal Cord, Brain, Pituitary, Lymph Node, Breast, Thymus, Bone

Sources

Publications for Spinal Meningioma

Articles related to Spinal Meningioma:

(show top 50) (show all 332)

#	Title	Authors	PMID	Year
1	Novel use of nonpenetrating titanium clips for pediatric primary spinal dural closure: A technical note. ⁶²	Shahrestani S...Levy ML	36084429	2022
2	Two predominant molecular subtypes of spinal meningioma: thoracic NF2-mutant tumors strongly associated with female sex, and cervical AKT1-mutant tumors originating ventral to the spinal cord. ⁶²	Hua L...Juratli TA	35943573	2022
3	Spinal Meningioma Surgery in Octogenarians: Functional Outcomes and Complications over a 2-Year Follow-Up Period. ⁶²	Lenga P...Unterberg AW	36295641	2022
4	Meningioma systematic reviews and meta-analyses: an assessment of reporting and methodological quality. ⁶²	George AM...Millward CP	36263847	2022
5	Spinal Meningioma Surgery through the Ages-Single-Center Experience over Three Decades. ⁶²	Gull HH...Ozkan N	36363510	2022
6	Functional Outcome after Spinal Meningioma Surgery. ⁶²	Jecko V...Champeaux-Depond C	35654108	2022
7	Characteristics of Patients Selected for Surgical Treatment of Spinal Meningioma. ⁶²	Spirollari E...Kinon MD	35779754	2022
8	Posterior-based resection of spinal meningiomas: an institutional experience of 141 patients with an average of 28 months of follow-up. ⁶²	Haddad AF...Ames CP	36152326	2022
9	Surgical Treatment of Spinal Meningiomas in the Elderly (≥75 Years): Which Factors Affect the Neurological Outcome? An International Multicentric Study of 72 Cases. ⁶²	Capo G...Barrey CY	36230713	2022
10	Delayed complications of intradural cement leakage after percutaneous vertebroplasty: A case report. ⁶²	Ma QH...Li JG	36157648	2022
11	Functional Outcome in Spinal Meningioma Surgery and Use of Intraoperative Neurophysiological Monitoring. ⁶²	Jesse CM...Seidel K	36010979	2022
12	Clipping Test of a Radiculomedullary Artery During Resection of a Dorsal Spinal Meningioma. ⁶²	Barrey CY...Vandenbulcke A	35562039	2022
13	Spinal Meningioma in Adults: Imaging Characteristics, Surgical Outcomes, and Risk Factors for Recurrence. ⁶²	Park BJ...Hitchon PW	35605940	2022
14	Extradural Spinal Lymphoplasmacyte-Rich Meningioma in the Thoracic Spine: A Case Report and Literature Review. ⁶²	Seo EH...Moon AR	36238911	2022
15	Minimally invasive surgery for intradural spinal meningioma: A new standard? A comparative study between minimally invasive and open approaches. ⁶²	Dauleac C...Assaker R	35123987	2022
16	Extradural Spinal Meningioma Mimicking a Schwannoma: Magnetic Resonance Imaging Findings. ⁶²	Garaud S...Vargas MI	34075867	2022
17	Surgical Resection of Dorsal Spinal Meningiomas with the Inner Dura Layer-An Improved Preservation Technique of Spinal Dura in 40 Cases. ⁶²	Wang X...Chen X	34999010	2022
18	Five-year cause-specific survival after meningioma surgery. A nationwide population-based study. ⁶²	Champeaux-Depond C...Froelich S	34906556	2022
19	Presentation and management of spinal meningioma and its association with breast carcinoma-case series and systematic review. ⁶²	Wang D...Nader-Sepahi A	35435093	2022
20	Functional Outcome After Spinal Meningioma Surgery. A Nationwide Population-Based Study. ⁶²	Champeaux-Depond C...Jecko V	35378584	2022
21	Recovery Potential of Spinal Meningioma Patients With Preoperative Loss of Walking Ability Following Surgery - A Retrospective Single-Center Study. ⁶²	Vasankari V...Korja M	35038831	2022
22	Incidental Spinal Meningioma on an 18F-Fluciclovine PET/CT. ⁶²	Marcus C...Schuster DM	35025777	2022
23	Proliferative Potential, and Inflammatory Tumor Microenvironment in Meningioma Correlate with Neurological Function at Presentation and Anatomical Location-From Convexity to Skull Base and Spine. ⁶²	Wach J...Guresir E	35205781	2022
24	The impact of body mass index and height on risk for primary tumours of the spinal cord, spinal meninges, spinal and peripheral nerves in 1.7 million norwegian women and men: a prospective cohort study. ⁶²	Gheorghiu A...Wiedmann MKH	35001805	2022
25	Spinal meningiomas in pediatric patients - A case series and literature review. ⁶²	Piatek P...Milczarek O	36324961	2022
26	Epidemiology and Survival after Spinal Meningioma Surgery: A Nationwide Population-Based Study. ⁶²	Jecko V...Champeaux-Depond C	35051328	2022
27	Case Report: Upper Thoracic Purely Extradural Spinal Meningioma With Nerve Root Attachment: A Case Report and Literature Review. ⁶²	Wang ZL...Liu P	35784918	2022
28	MAC-spinal meningioma score: A proposal for a quick-to-use scoring sheet of the MIB-1 index in sporadic spinal meningiomas. ⁶²	Wach J...Guresir E	36091152	2022
29	Multiple ossified spinal meningiomas in the thoracic spine: A case report and literature review. ⁶²	Dong C...Ma Y	36268212	2022
30	Cervical Spine Inhomogeneously Enhancing Lesion: Avoiding Confirmation Bias. ⁶²	Penner F...Zenga F	35110934	2022
31	Novel Dural-Splitting Operative Technique for Excision of Ventrally Located Spinal Meningiomas. ⁶²	Okura H...Cusimano MD	34601172	2022
32	Correlations Among Consistency, Computed Tomography Values, and Histopathological Subtypes of Spinal Meningioma. ⁶²	Aoyama T...Hongo K	34955539	2021
33	Health-Related Quality of Life and Return to Work after Surgery for Spinal Meningioma: A Population-Based Cohort Study. ⁶²	Pettersson-Segerlind J...Elmi-Terander A	34944991	2021
34	Microsurgical Resection of Radiation-Induced Cervical Spinal Intradural Extramedullary Meningioma: Dural Splitting Resection. ⁶²	Nguyen VN...Arnautovic KI	34454072	2021
35	Spinal Meningiomas: Influence of Cord Compression and Radiological Features on Preoperative Functional Status and Outcome. ⁶²	Baro V...Tessitore E	34439337	2021
36	Spinal meningioma surgery in the elderly: who can benefit from it? ⁶²	Engel DC...Ebner FH	30468359	2021
37	Characteristics of cases with and without calcification in spinal meningiomas. ⁶²	Kobayashi K...Imagama S	34119267	2021
38	Clinical characteristics and management differences for grade II and III spinal meningiomas. ⁶²	Krauss WE...Bydon M	33973145	2021
39	Clinical features and prognostic factors in spinal meningioma surgery from a multicenter study. ⁶²	Kobayashi K...Imagama S	34079036	2021
40	Functional outcome and morbidity after microsurgical resection of spinal meningiomas. ⁶²	Kilinc F...Behmanesh B	33932928	2021
41	Demographic and socioeconomic disparities of benign and malignant spinal meningiomas in the United States. ⁶²	Ghaffari-Rafi A...Leon-Rojas J	33068594	2021
42	Paraplegia due to spinal meningioma during the third trimester of pregnancy: case report and literature review. ⁶²	Antolinez Ayala VE...Castellanos Penaranda C	33859165	2021
43	Predictive Value of Heterogeneously Enhanced Magnetic Resonance Imaging Findings With Computed Tomography Evidence of Calcification for Severe Motor Deficits in Spinal Meningioma. ⁶²	Ono K...Matsuda S	33285060	2021
44	Surgical results of the resection of spinal meningioma with the inner layer of dura more than 10 years after surgery. ⁶²	Tominaga H...Taniguchi N	33603112	2021
45	The protean manifestations of central nervous system IgG4-related hypertrophic pachymeningitis: a report of two cases. ⁶²	Woo PYM...Chan KY	33536053	2021
46	The incidence of venous thromboembolism following surgical resection of intracranial and intraspinal meningioma. A systematic review and retrospective study. ⁶²	Fluss R...Lasala P	33444944	2021
47	Heterotopic ossification in psammomatous spinal meningioma: a diagnostic controversy. ⁶²	Wong YP...Palaniandy K	34093948	2021
48	Thoracic meningioma with ossification: Case report. ⁶²	Buchanan D...Buchanan RI	34754555	2021
49	Age at Diagnosis and Baseline Myelomalacia Sign Predict Functional Outcome After Spinal Meningioma Surgery. ⁶²	Wach J...Scorzin J	34277695	2021
50	Purely extradural spinal meningioma: A case report and literature review. ⁶²	Shui C...Davies M	34513194	2021

Sources

Genes for Spinal Meningioma

Genes related to Spinal Meningioma (0 elite genes):

(show all 16)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	SMARCE1	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily E, Member 1	Protein Coding	7.84	DISEASES inferred ¹⁴
2	NF2	NF2, Moesin-Ezrin-Radixin Like (MERLIN) Tumor Suppressor	Protein Coding	7.69	DISEASES inferred ¹⁴
3	SMARCB1	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, Subfamily B, Member 1	Protein Coding	6.37	DISEASES inferred ¹⁴
4	TRAF7	TNF Receptor Associated Factor 7	Protein Coding	6.26	DISEASES inferred ¹⁴
5	LZTR1	Leucine Zipper Like Transcription Regulator 1	Protein Coding	6.06	DISEASES inferred ¹⁴
6	PGR	Progesterone Receptor	Protein Coding	5.31	DISEASES inferred ¹⁴
7	SMARCC2	SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin Subfamily C Member 2	Protein Coding	5.26	DISEASES inferred ¹⁴
8	BCL7B	BAF Chromatin Remodeling Complex Subunit BCL7B	Protein Coding	5.2	DISEASES inferred ¹⁴
9	EPB41	Erythrocyte Membrane Protein Band 4.1	Protein Coding	5.02	DISEASES inferred ¹⁴
10	FAT2	FAT Atypical Cadherin 2	Protein Coding	5	DISEASES inferred ¹⁴
11	NF1	Neurofibromin 1	Protein Coding	4.99	DISEASES inferred ¹⁴
12	PHF10	PHD Finger Protein 10	Protein Coding	4.88	DISEASES inferred ¹⁴
13	ARID1A	AT-Rich Interaction Domain 1A	Protein Coding	4.85	DISEASES inferred ¹⁴
14	MIB1	MIB E3 Ubiquitin Protein Ligase 1	Protein Coding	4.84	DISEASES inferred ¹⁴
15	KLF4	KLF Transcription Factor 4	Protein Coding	4.8	DISEASES inferred ¹⁴
16	PBRM1	Polybromo 1	Protein Coding	4.79	DISEASES inferred ¹⁴

Sources

Variations for Spinal Meningioma

Sources

Expression for Spinal Meningioma

Search GEO for disease gene expression data for Spinal Meningioma.

Sources

Pathways for Spinal Meningioma

Pathways related to Spinal Meningioma according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Assembly of the pre-replicative complex ⁶⁶ Show member pathways DNA Replication ⁶⁶ DNA Replication Pre-Initiation ⁶⁶ RUNX1 regulates transcription of genes involved in differentiation of HSCs ⁶⁶ Transcriptional regulation by RUNX1 ⁶⁶	12.77	SMARCE1 SMARCC2 SMARCB1 PBRM1 ARID1A
2	Chromatin organization ⁶⁶ Show member pathways Chromatin modifying enzymes ⁶⁶ HATs acetylate histones ⁶⁶	12.6	SMARCE1 SMARCC2 SMARCB1 PBRM1 ARID1A
3	AMPK Enzyme Complex Pathway ⁶⁴ Show member pathways Chromatin Remodeling ⁶⁴	11.85	SMARCE1 SMARCC2 SMARCB1 ARID1A
4	Thermogenesis ⁷⁴ Show member pathways mitochondrial L-carnitine shuttle ⁶¹	11.61	SMARCE1 SMARCC2 SMARCB1 ARID1A
5	Transcription Ligand-dependent activation of the ESR1/SP pathway ²² Show member pathways Development Ligand-dependent activation of the ESR1/AP-1 pathway ²²	11.3	SMARCE1 SMARCC2 SMARCB1 ARID1A
6	Tumor suppressor activity of SMARCB1 ⁷⁴ Show member pathways GLI proteins bind promoters of Hh responsive genes to promote transcription ⁶⁶	10.79	SMARCE1 SMARCC2 SMARCB1 ARID1A
7	RUNX1 interacts with co-factors whose precise effect on RUNX1 targets is not known ⁶⁶	10.6	SMARCE1 SMARCC2 SMARCB1 PBRM1 ARID1A
8	Validated nuclear estrogen receptor beta network ⁶¹	10.58	SMARCE1 SMARCB1

Sources

GO Terms for Spinal Meningioma

Cellular components related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 12)

#	Name	GO ID	Score	Top Affiliating Genes
1	chromatin	GO:0000785	10.41	SMARCE1 SMARCC2 SMARCB1 PHF10 PGR PBRM1
2	kinetochore	GO:0000776	10.18	PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
3	nuclear matrix	GO:0016363	10.13	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1
4	nuclear chromosome	GO:0000228	9.97	PBRM1 SMARCB1 SMARCE1
5	nBAF complex	GO:0071565	9.97	SMARCC2 SMARCB1 ARID1A SMARCE1
6	brahma complex	GO:0035060	9.92	SMARCE1 SMARCC2 SMARCB1 ARID1A
7	bBAF complex	GO:0140092	9.86	SMARCE1 SMARCC2 SMARCB1 ARID1A
8	RSC-type complex	GO:0016586	9.85	PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
9	npBAF complex	GO:0071564	9.65	SMARCE1 SMARCC2 SMARCB1 PHF10 ARID1A
10	DNA packaging complex	GO:0044815	9.58	ARID1A SMARCB1 SMARCC2
11	SWI/SNF superfamily-type complex	GO:0070603	9.51	SMARCB1 ARID1A
12	SWI/SNF complex	GO:0016514	9.47	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B

Biological processes related to Spinal Meningioma according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of transcription by RNA polymerase II	GO:0006357	10.49	ARID1A BCL7B KLF4 PBRM1 PGR PHF10
2	chromatin remodeling	GO:0006338	10.3	ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
3	nervous system development	GO:0007399	10.22	SMARCE1 SMARCC2 SMARCB1 PHF10 ARID1A
4	negative regulation of cell population proliferation	GO:0008285	10.21	SMARCB1 PBRM1 NF2 NF1 KLF4
5	positive regulation of myoblast differentiation	GO:0045663	10.21	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 ARID1A
6	positive regulation of cell differentiation	GO:0045597	10.21	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 NF2
7	positive regulation of stem cell population maintenance	GO:1902459	10.18	SMARCE1 SMARCB1 PHF10 BCL7B ARID1A
8	positive regulation of T cell differentiation	GO:0045582	10.18	ARID1A PBRM1 PHF10 SMARCB1 SMARCC2 SMARCE1
9	regulation of G1/S transition of mitotic cell cycle	GO:2000045	10.17	ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
10	nucleosome disassembly	GO:0006337	10.1	ARID1A SMARCB1 SMARCC2 SMARCE1
11	positive regulation of double-strand break repair	GO:2000781	10.1	ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
12	regulation of mitotic metaphase/anaphase transition	GO:0030071	10	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B
13	chromatin organization	GO:0006325	9.92	SMARCE1 SMARCC2 SMARCB1 PBRM1 ARID1A
14	negative regulation of Schwann cell proliferation	GO:0010626	9.85	NF2 NF1
15	Schwann cell proliferation	GO:0014010	9.81	NF2 NF1
16	regulation of nucleotide-excision repair	GO:2000819	9.8	ARID1A BCL7B PBRM1 PHF10 SMARCB1 SMARCC2
17	regulation of G0 to G1 transition	GO:0070316	9.47	SMARCE1 SMARCC2 SMARCB1 PHF10 PBRM1 BCL7B